Hims & Hers
Hims & Hers Health, Inc. (NYSE: HIMS)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Platform, not a drug; markets FDA-approved generics and compounded products
Reference only. Not medical advice.
What can go wrong
The prescriber-also-seller structure creates a documented conflict: the same commercial entity that profits from a prescription arranges the clinical encounter that authorizes it. Compounded GLP-1 products are not FDA-approved and their quality depends on the compounding pharmacy; Novo Nordisk alleged in its June 2025 termination that some telehealth-channel compounded drugs used active ingredients from uninspected overseas suppliers. Subscription lock-in and auto-refill billing generate recurring consumer complaints.
This is something to take to a clinician. The Atlas can tell you what is known about hims & hers in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hims & Hers is the largest publicly traded direct-to-consumer telehealth company in men's and women's health, built on subscription prescriptions for erectile dysfunction, hair loss, mental health, and weight loss. It went public via a $1.6B SPAC merger with Oaktree Acquisition Corp in January 2021 and reported $1.5B in 2024 revenue (up ~69% YoY) with 2.2M subscribers. Its most consequential and contested chapter is compounded GLP-1 semaglutide: the company generated over $225M from compounded GLP-1 in 2024, aired a Super Bowl LIX (2025) ad, briefly partnered with Novo Nordisk in April 2025, and had that partnership terminated by Novo Nordisk in June 2025 over allegations of illegal mass compounding and deceptive marketing.
The category-defining men's-health storefront, and the loudest cautionary tale in compounding.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Business model, not pharmacology: Hims routes a self-reported intake through an affiliated prescriber, then fulfills recurring prescriptions via partner or in-house pharmacies on a subscription basis. Revenue scales with subscriber count, average order value, and retention. Vertical integration into compounding and affiliated pharmacy operations lets the company capture pharmacy margin as well as the consult and platform fee.
What people get wrong
Often saidThe Novo Nordisk partnership validated Hims' GLP-1 business
ActuallyNovo Nordisk publicly terminated the collaboration within roughly two months, accusing Hims of illegal mass compounding under a false guise of personalization and deceptive marketing. A brief partnership announcement is not a durable endorsement.
Often saidCompounded semaglutide from a telehealth platform is equivalent to Wegovy
ActuallyCompounded products are not FDA-approved and are not evaluated for the safety, efficacy, or manufacturing quality of the branded drug. Equivalence is not established.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Andrew Dudum (co-founder/CEO), early venture backers, and public shareholders. The company profits at multiple points of the same transaction: the consult, the platform subscription, and increasingly the pharmacy fulfillment margin.
At a glance
- IPO
- SPAC merger with Oaktree Acquisition Corp, Jan 2021, ~$1.6B valuation
- 2024 revenue
- $1.5B (reported, up ~69% YoY)
- 2024 subscribers
- 2.2M (reported)
- GLP-1 revenue 2024
- >$225M (reported)
- Ticker
- NYSE: HIMS
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hims & Hers. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.